DermTech, Inc.

DermTech, Inc. (NASDAQ: DMTK) is a precision dermatology company that entered public markets through a SPAC merger with Constellation Alpha Capital Corp in 2019, with Constellation Alpha serving as sponsor. Operating in the molecular diagnostics and healthcare sector, DermTech developed a non-invasive genomic testing platform focused on early melanoma detection, marketed as the DermTech Melanoma Test. The company filed a 10-K/A amended annual report with the SEC on April 26, 2024, reflecting an active regulatory disclosure posture as it navigated challenging financial conditions in the post-merger period. DMTK represents a prominent de-SPAC case study in the precision medicine space. For complete filing history, financial data, and SPAC transaction details on DermTech and thousands of other de-SPAC companies, sign up for full access at SpacDesk.